New research indicates that people who discontinue new slimming jabs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who halt traditional lifestyle programs.
Findings released in a prominent health publication demonstrates that while obese people often shed about a fifth of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.
"Users buying these treatments should be cognizant of the danger of quick weight regain when the therapy concludes," warns researcher Dr. Susan Jebb.
This pace of regain implies a return to starting weight within about a year and a half.
Comparing Treatments
The study, which reviewed 37 of trials involving over 9,000 of patients, compared the results of GLP-1 agonists with conventional dieting.
Scientists emphasize that people who lose weight through diet and exercise generally experience a slower creep back—approximately 100 grams monthly—once they finish.
The Reason for the Fast Rebound
Doctors suggest the mechanism of the jabs explains the accelerated weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of GLP-1 concentrations several times higher than normal might result in the body to produce less of its own natural hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication leads to hunger is no longer kept in check, making excessive eating a significant risk."
A Lifelong Disease?
Health authorities suggest the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts say that, given the high risk of weight regain, the therapy is often long-term.
This perspective is supported by pharmaceutical companies, who note that the results "underscore the chronic character of excess weight," similar to managing conditions like diabetes.
User Experiences
Users who have discontinued the medication describe a intense resurgence of hunger.
"It was like a trigger flipping and you become extremely hungry," recalled one woman.
This difficulty is worsened if users have not established sustainable lifestyle or habit modifications during therapy.
Growing Adoption
Figures indicate that millions of adults in the UK have used these injections in the past year, with desire being substantial.
- Use is greater among women than males.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent cure and lasting health benefits likely depends on integrated lifestyle management.
